Data & Methodology

First-party. Operationally generated.
Auditable by any partner.

Every record in Summit's data layer originated from a real patient who completed an unbranded condition campaign. No purchased lists, no probabilistic appends, no modeled lookalikes. Methodology, intake logs, and consent records are available for brand-partner audit under NDA.

The Data Brief

Download the audit-ready data brief.

Full methodology, tier architecture, compliance posture, and cross-tier proof in a single PDF. Forward to your data team or use it as the starting brief for procurement. One email. No newsletter. We respond within one business day.

One email. No newsletter. We respond within one business day.

Condition‑Confirmed Inquiries
0
Operationally generated since 2016
Condition Pathways
9
Diabetes · OSA · Cardiac · GLP-1 · More
Annual Rx Fulfillment Events
0
Tx-verified treatment records on file
Cross-Tier Phone Matches
386,000+
T3 ↔ T1 and T3 ↔ T2 identity graph
GLP-1 Patients
19,470
Standalone GLP-1 cohort, BAA-gated
Cohort Refresh
Monthly
Continuous ingestion from live campaigns

The Data Layers

T3 is the asset.
Everything below it proves T3 converts.

T3 · Condition-Confirmed Inquiries

The headline asset. Every record is a real person who completed a condition-specific intake during a Summit-operated unbranded campaign — landing page form fill, click-to-call inbound, or live transfer. They self-identified. They consented. They asked for information. No competitor can access this data — exclusively licensed through 2046.

0
records
T2 · Dx-Qualified — 218,071

Patients clinically qualified for therapy but blocked on logistics: insurance authorization, missing documentation, coverage gaps. The exact audience access programs and patient services teams are built for.

218,071
records
T1 · Tx-Verified — 140,216 patients · 1,008,348 Rx events

Patients with verified treatment on file. Full multi-year Rx supply cadence per patient. Average 7.2 fills on record. Available under PHI tier with a signed BAA.

1,008,348
Rx events
HCP Layer · 166,464 prescriber NPIs

Prescribers linked to confirmed Summit patient volume. Warm prescribers attached to real patient panels — not cold specialty codes.

166,464
NPIs
Cardiac Cohort · 433,128 patients

Separate device-derived cohort. Standalone clinical asset, available for cardiac-specific activations or as enrichment within a broader license.

433,128
patients
Standalone Campaign Tiers

Polypharmacy (~5.84M), Medicare Advantage (1.16M), and GLP-1 (19,470) — built for specific condition campaigns. Available independently or as enrichment within any license structure.

5.84M+
polypharmacy

Every layer connects back to T3 records by phone hash. The tiers below prove T3 converts — not a lead list.

The Cross-Tier Graph

T3 isn't a lead list.
The graph proves it.

The most common objection to any patient inquiry dataset is "this is just a lead list." Summit's answer is the cross-tier graph — every T3 record can be matched by phone hash to T1, T2, HCP, and downstream Rx fulfillment events.

Annual Rx Fulfillment Events
0
Multi-year Rx supply cadence per patient, averaged 7.2 fills on file. The downstream proof that T3 converts.
Total Cross-Tier Phone Matches
386,000+
Phone-hash matches across T3 ↔ T1 and T3 ↔ T2. The full identity graph showing inquiry-to-treatment flow at scale.

The graph is the answer to "is T3 just a lead list?" It isn't — it's the operational top of a funnel that produced over a million verified Rx events downstream.

Compliance & Defensibility

Every record is defensible.
Here's why.

The dataset is not a model, not a purchased list, not a probabilistic append. It is the operational output of a decade of condition-specific patient acquisition campaigns — built operationally, refreshed continuously, exclusive for 20 years.

First-Party
Self-identified on a Summit campaign
No purchased lists, no third-party append, no modeled lookalikes.
Consent-Based
Captured at the point of intake
Scope, duration, and opt-out tracked per record at intake.
HIPAA Safe Harbor
De-identified & compliant HIPAA Safe Harbor 45 CFR §164.514(b)(2)
No PII retained in the licensed dataset. BAA flow-down available for PHI tier.
Exclusive Through 2046
20-year moat, no competitor access
The exclusivity itself is the competitive advantage. It cannot be replicated.